Apimeds Pharmaceuticals US I
13F holders, Q2 2026 (June 30)7holders +1
2new positions
1sold out
$0.90avg. 13F price*
At the end of Q2 2026, 7 institutions reported holding Apimeds Pharmaceuticals US I in their 13F filings, up 1 from Q1 2026. 2 opened new positions and 1 sold out. The largest holders were Hemenway Trust Co LLC ($247K), Vanguard Capital Management LLC ($57K) and Geode Capital Management, LLC ($32K).
- Company
- Apimeds Pharmaceuticals US I
- CUSIP
- 03771D102
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2026 → Q2 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $16K |
| Exits | 1 | $19K |
All 13F filers, Q1 2026 → Q2 2026: 25,288 shares bought and 47,762 shares sold, net −22,474 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 7 holders
| Hemenway Trust Co LLC | 0.02% | No change | 274,000 | $247K |
| Vanguard Capital Management LLC | 0.00% | Reduce -33.6% | 63,654 | $57K |
| Geode Capital Management, LLC | 0.00% | Reduce -12.3% | 35,114 | $32K |
| Vanguard Fiduciary Trust Co. | 0.00% | No change | 24,039 | $22K |
| Jane Street Group, LLC | 0.00% | New | 15,993 | $14K |
| UBS Group AG | 0.00% | Add +182.3% | 11,818 | $11K |
| Tower Research Capital LLC (TRC) | 0.00% | New | 1,664 | $1K |
"% of holder's portfolio" is APIMEDS PHARMACEUTICALS US I's weight in each manager's 13F, not the share of Apimeds Pharmaceuticals US I the manager owns.